title: In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy.
abstract: BACKGROUND
  The diabetic state, in both humans and experimental animals, is associated with oxidative stress. Lipid peroxidation of nerve membranes has been suggested as a mechanism by which peripheral nerve ischemia and hypoxia could cause neuropathy. Lipoic acid (LA) is a powerful inhibitor of iron-dependent lipid peroxidation and reactive oxygen species. The treatment of diabetic peripheral and cardiac autonomic neuropathy with LA is based on good clinical and experimental evidence.
  
  
  METHODS
  To investigate the magnitude of the oxidative stress, serum ceruloplasmin (Cp) and lipid peroxide (Lp) levels were measured in 10 patients with diabetic neuropathy, before and 70 days after treatment with single dose of 600 mg LA/day. For other 12 healthy age- and sex-matched control subjects the serum Cp and Lp levels were evaluated.
  
  
  RESULTS
  Our results show that hyperglycemia is a factor for an increase in serum ceruloplasmin in patients with diabetic neuropathy compared to healthy subjects (p < 0.0001). High serum ceruloplasmin (Cp) level in patients with diabetes may be related to antioxidant defense. The treatment of diabetic neuropathy with LA does not affect significantly the serum Cp activity. The serum Lp levels after LA administration were significantly lower (p < 0.005) than those before treatment.
  
  
  CONCLUSIONS
  The antioxidant therapy with LA improves and may prevent diabetic neuropathy. This improvement is associated with a reduction in the indexes of lipid peroxidation. Oxidative stress appears to be primarily due to the processes of nerve ischemia and hyperglycemia autooxidation.
authors.affiliation: Diabetes Center & Clinic, Cluj Napoca.
authors.forename: L
authors.initials: L
authors.lastname: Androne
authors.forename: N A
authors.initials: NA
authors.lastname: Gavan
authors.forename: I A
authors.initials: IA
authors.lastname: Veresiu
authors.forename: R
authors.initials: R
authors.lastname: Orasan
mesh_terms: D000368:Aged; D000975:Antioxidants / Q000627:therapeutic use*; D002570:Ceruloplasmin; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D006943:Hyperglycemia; D015227:Lipid Peroxidation / Q000187:drug effects; D008054:Lipid Peroxides / Q000097:blood; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects; D008063:Thioctic Acid / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D008054:Lipid Peroxides; D008063:Thioctic Acid; D002570:Ceruloplasmin